Earnings Routine +

Promino Nutritional Sciences Reports Fiscal 2025 Results, Delivering Revenue Growth and Improved Financial Performance

Promino Confirms Turnaround Trajectory But Cash Burn Remains Critical Risk

By The Northwire Desk — AI Analysis May 04, 2026 · 07:01 MUSL · 0.035 Promino Nutritional Sciences Inc

Executive Summary

Fiscal 2025 Results: Revenue grew to over $2.1 million from approximately $260,600 in the prior year (8x growth). Net loss decreased to $3.0 million from $7.1 million.
Governance Cleanup: Cease-trade order revoked; enhanced internal controls implemented; 2024 financial statements restated for transparency regarding share-based payments and liabilities.
Operations: Expanded distribution of Rejuvenate Muscle Health™; initiated production run of 3.5 million servings across four flavors (Mango, Grape, etc.).
Management Commentary: CEO Vito Sanzone emphasizes disciplined growth, expanded distribution, and strengthened operational foundation following financial infrastructure investments.

Material Impact

Revenue Validation: The $2.1 million revenue figure validates the December 2025 announcement of $1.88 million YTD sales through October. This confirms the commercial traction was not a one-off but sustained growth into Q4.
Loss Reduction: While losses decreased significantly ($7.1M to $3.0M), the company remains unprofitable with expenses exceeding revenue by ~$1.3 million. This necessitates continued capital raises, which is consistent with historical financing patterns.
Governance Risk Mitigation: The revocation of the cease-trade order and restatement completion removes a major regulatory overhang that previously suppressed valuation. However, this was largely anticipated following the December 2025 trading halt lift.
Financing Context: The news aligns with the April 2026 private placement ($1.2M) intended to fund inventory production. The earnings confirm the capital is being deployed into revenue-generating assets (inventory).
Market Expectation: Given the December 2025 guidance and subsequent financing rounds, this result is in line with expectations rather than a surprise upside that would materially re-rate the stock.

MUSL · Price

Company Overview

Company: Promino Nutritional Sciences Inc., listed on the Canadian Securities Exchange (CSE).
Flagship Product: Rejuvenate Muscle Health™. An amino-acid formulation marketed for muscle preservation, specifically targeting consumers using GLP-1 weight-loss therapies who need to maintain lean mass.
Product Format: Currently powder sticks; Ready-to-Drink (RTD) version planned for Q3 2026.
Distribution: Approximately 10,000 retail doors in North America as of March/April 2026 updates. Strong Amazon presence (>4,000 units/month).
Strategic Partnerships: NCAA Division I athlete platform with Virginia Military Institute (VMI) launched April 2026 to validate efficacy and build brand credibility.

More from Promino Nutritional Sciences Inc